Zevra Therapeutics, Inc. (ZVRA)

NASDAQ: ZVRA · IEX Real-Time Price · USD
5.94
+0.22 (3.85%)
At close: Mar 27, 2024, 4:00 PM
6.00
+0.06 (1.01%)
After-hours: Mar 27, 2024, 6:35 PM EDT

Company Description

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.

The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).

The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate.

It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial.

In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA.

The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.

Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Zevra Therapeutics, Inc.
Zevra Therapeutics logo
Country United States
Founded 2006
IPO Date Apr 16, 2015
Industry Biotechnology
Sector Healthcare
Employees 32
CEO Neil F. McFarlane

Contact Details

Address:
1180 Celebration Boulevard, Suite 103
Celebration, Florida 34747
United States
Phone (321) 939-3416
Website zevra.com

Stock Details

Ticker Symbol ZVRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001434647
ISIN Number US4884452065
Employer ID 20-5894398
SIC Code 2834

Key Executives

Name Position
R. LaDuane Clifton CPA Chief Financial Officer, Secretary, Treasurer and Director
Neil F. McFarlane President, Chief Executive Officer and Director
Christal M. M. Mickle M.A. Co-Founder and Chief Development Officer
Dr. Sven Guenther Ph.D. Chief Scientific Officer
Nichol L. Ochsner Vice President of Investor Relations and Corporate Communications
Dr. Christopher M. Lauderback Ph.D. Senior Vice President of Manufacturing
Dr. Rene A. Braeckman Ph.D. Senior Vice President of Clinical Development
Joshua M. Schafer M.B.A. Chief Commercial Officer, Executive Vice President of Business Development and Director
Dr. Daniel Gallo Ph.D. Senior Vice President of Medical Affairs and Advocacy
Dr. Adrian Quartel FFPM, M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 27, 2024 8-K Current Report
Mar 5, 2024 8-K Current Report
Mar 4, 2024 8-K Current Report
Feb 28, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 5, 2024 S-3 Registration statement under Securities Act of 1933
Feb 5, 2024 8-K/A [Amend] Current report
Jan 29, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 23, 2024 8-K Current Report
Jan 8, 2024 8-K Current Report